Affiliations: [a] Dipartimento di Istologia, Embriologia e Biologia Applicata, Università di Bologna, Bologna, Italy | [b] Centro di Ricerca in Genetica Molecolare “Fondazione CARISBO”, Bologna, Italy | [c] Dipartimento Emergenza/Urgenza, Chirurgia Generale e dei Trapianti, Università di Bologna, Bologna, Italy
Correspondence:
[*]
Corresponding author: Rossella Solmi, Dipartimento di Istologia, Embriologia e Biologia Applicata, Via Belmeloro, 8 40126 Bologna, Italy. Tel.: +39 051 2094100 2094109; Fax: +39 051 2094110; E-mail: [email protected].
Note: [1]
Equal contributors.
Abstract: Epidermal growth factor receptor (EGFR) family members (EGFR, HER2, HER3 and HER4) have been extensively investigated for its possible involvement in cancer development and progression. In colorectal cancer (CRC) EGFR family has been found frequently over-expressed, thus therapy targeting EGFR has been developed. Interestingly, it has been observed that genetic variants in these receptors may alter the therapeutic efficacy of EGFR inhibitors. Polymorphic variants in members of the EGFR family could influence different biologic activities, such as ligands affinity, dimerization efficiency, kinase activity, expression levels, with a consequent impact in signalling pathways and cell behaviour. This study aimed to verify whether single nucleotide polymorphisms (SNPs) of EGFR family members could represent susceptibility factors able to influence the risk to develop CRC. Peripheral blood of 70 Italian colon cancer patients and 72 healthy controls was used as a source of genomic DNA to investigate EGFR, HER2 and HER3 common non-synonymous SNPs. Genetic association tests were performed to verify a possible relationship with CRC. Evidence of genotype association was found for the R521K EGFR polymorphism under a dominant mode of inheritance (Mid-P=0.031). Genotypes with the variant allele of EGFR R521K SNP confer a risk reduction to develop CRC.
